PD‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐PD‐1/PD‐L1 clinical trials

Publisher： John Wiley & Sons Inc

E-ISSN： 1755-148x|28|3|245-253

ISSN： 1755-1471

Source： PIGMENT CELL & MELANOMA RESEARCH, Vol.28, Iss.3, 2015-05, pp. : 245-253

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

RAC1 P29S regulates PD‐L1 expression in melanoma

By  

PIGMENT CELL & MELANOMA RESEARCH, Vol. 28, Iss. 5, 2015-09 ,pp. : 590-598

John Wiley & Sons Inc

Access to resources Recommend Favorite

PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression

By Šmahel Michal  

International Journal of Molecular Sciences, Vol. 18, Iss. 6, 2017-06 ,pp. : 1331-1331

MDPI

Access to resources Recommend Favorite

Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors

By Abdin Shifaa M.   Zaher Dana M.   Arafa El-Shaimaa A.   Omar Hany A.  

Cancers, Vol. 10, Iss. 2, 2018-01 ,pp. : 32-32

MDPI

Access to resources Recommend Favorite

Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment

By Tunger Antje   Kießler Maximilian   Wehner Rebekka   Temme Achim   Meier Friedegund   Bachmann Michael   Schmitz Marc  

Biomedicines, Vol. 6, Iss. 1, 2018-03 ,pp. : 26-26

MDPI

Access to resources Recommend Favorite

Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients

By Botti Gerardo   Collina Francesca   Scognamiglio Giosuè   Rao Federica   Peluso Valentina   De Cecio Rossella   Piezzo Michela   Landi Gabriella   De Laurentiis Michelino   Cantile Monica   Di Bonito Maurizio  

International Journal of Molecular Sciences, Vol. 18, Iss. 2, 2017-02 ,pp. : 459-459

MDPI

Access to resources Recommend Favorite